USFDA inspects Jubilant Generics API manufacturing facility

Last Updated : Mar 22 2019 | 9:04 AM IST

Jubilant Life Sciences has been informed by the U.S. Food and Drug Administration (USFDA), in correspondence dated 13 March 2019, received on 21 March 2019 that the inspection from December 10-18, 2018 at the Jubilant Generics API manufacturing facility, in Nanjangud, Mysore, has been classified as Official Action Indicated (OAI). The USFDA also stated that the facility might be subject to a cGMP regulatory or enforcement action based on this inspection, and that FDA could withhold approval of any pending applications or supplements in which this facility is listed.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

Already subscribed? Log in

Subscribe to read the full story →

^*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%

*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

In-depth market analysis & insights with access to The Smart Investor

Ad-free Reading

Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

Access Business Standard across devices — mobile, tablet, or PC, via web or app

SAVE 25%

Subscribe for ₹2,700 / 1 Year

Connect with us on WhatsApp

USFDA inspects Jubilant Generics API manufacturing facility